See more : Azelis Group NV (AZLGF) Income Statement Analysis – Financial Results
Complete financial analysis of iTeos Therapeutics, Inc. (ITOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iTeos Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Devro plc (DVO.L) Income Statement Analysis – Financial Results
- EyePoint Pharmaceuticals, Inc. (EYPT) Income Statement Analysis – Financial Results
- Cni Research Limited (CNIRESLTD.BO) Income Statement Analysis – Financial Results
- Aurobindo Pharma Limited (AUROPHARMA.BO) Income Statement Analysis – Financial Results
- CoBank, ACB (CKNQP) Income Statement Analysis – Financial Results
iTeos Therapeutics, Inc. (ITOS)
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 12.60M | 267.63M | 344.78M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 898.00K | 813.00K | 615.00K | 535.00K | 611.00K | 505.00K |
| Gross Profit | 11.70M | 266.82M | 344.16M | -535.00K | -611.00K | -505.00K |
| Gross Profit Ratio | 92.87% | 99.70% | 99.82% | 0.00% | 0.00% | 0.00% |
| Research & Development | 113.30M | 97.36M | 59.37M | 29.90M | 19.21M | 17.19M |
| General & Administrative | 50.40M | 43.95M | 40.51M | 15.34M | 8.84M | 4.31M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.40M | 43.95M | 40.51M | 15.34M | 8.84M | 4.31M |
| Other Expenses | 0.00 | -3.26M | -10.18M | -5.93M | -4.78M | -163.00K |
| Operating Expenses | 163.70M | 138.04M | 89.69M | 39.31M | 23.27M | 17.82M |
| Cost & Expenses | 163.70M | 138.04M | 89.69M | 39.31M | 23.27M | 17.82M |
| Interest Income | 31.77M | 11.36M | 78.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.00K |
| Depreciation & Amortization | 898.00K | 813.00K | 615.00K | 535.00K | 611.00K | 505.00K |
| EBITDA | -151.10M | 148.38M | 257.08M | -37.84M | -21.72M | -17.48M |
| EBITDA Ratio | -1,199.69% | 48.72% | 74.16% | 0.00% | 0.00% | 0.00% |
| Operating Income | -151.10M | 126.32M | 244.90M | -45.24M | -28.05M | -21.50M |
| Operating Income Ratio | -1,199.69% | 47.20% | 71.03% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 42.07M | 22.41M | 11.56M | 7.15M | 5.71M | 3.46M |
| Income Before Tax | -109.03M | 148.74M | 256.46M | -38.09M | -22.34M | -18.05M |
| Income Before Tax Ratio | -865.66% | 55.58% | 74.39% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.61M | 52.08M | 41.94M | -57.00K | 119.00K | 11.00K |
| Net Income | -112.64M | 96.65M | 214.52M | -38.03M | -22.45M | -18.06M |
| Net Income Ratio | -894.34% | 36.11% | 62.22% | 0.00% | 0.00% | 0.00% |
| EPS | -3.15 | 2.72 | 6.10 | -1.09 | -0.64 | -2.40 |
| EPS Diluted | -3.15 | 2.56 | 5.68 | -1.09 | -0.64 | -2.40 |
| Weighted Avg Shares Out | 35.76M | 35.55M | 35.18M | 35.04M | 35.02M | 7.51M |
| Weighted Avg Shares Out (Dil) | 35.76M | 37.77M | 37.77M | 35.04M | 35.02M | 7.51M |
ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The Top 7 Growth Stocks in Biotech
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
iTeos Therapeutics: Able To Pull In Big Pharma Deals, Needs Follow-Through
iTeos Therapeutics, Inc. has a major deal with GSK, but a rival drug failed, bringing iTeos Therapeutics down. This happened once before with another program.
iTeos to Present at Cowen 43rd Annual Health Care Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D.,...
The 7 Best Biotech Stocks to Buy for February 2023
While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than...
iTeos to Present at SVB Securities Global Biopharma Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 07, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D.,...
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.
iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D.,...
iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 22, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D.,...
ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -57.14% and 53.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports